Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill